Aging with HIV: The Burden of Comorbidities, Polypharmacy, and Drug Interactions in Korean People Living with HIV Aged ≥50 Years
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background The life expectancy of people living with human immunodeficiency virus (PLWH) has significantly improved with advancements in antiretroviral therapy (ART). However, aging PLWH face a growing burden of non-communicable diseases (NCDs), polypharmacy, and drug-drug interactions (DDIs), which pose challenges in their management. This study investigates the prevalence of NCDs, polypharmacy, and DDIs among PLWH aged ≥50 years in Korea and their impact on quality of life (QOL). Materials and Methods A cross-sectional study was conducted among 243 PLWH aged ≥50 years receiving ART for at least three months at three university hospitals in Korea between January and July 2022. Data were collected through electronic medical records and personal interviews, assessing demographics, comorbidities, polypharmacy, ART adherence, and QOL using the Korean version of WHOQOL-HIV BREF scale. Potential DDIs were analyzed using the University of Liverpool HIV Drug Interaction Database, and potentially inappropriate medications (PIMs) were identified using the 2023 American Geriatrics Society Beers Criteria. We classified participants into three age groups: 50–<65 years, 65–<75 years, and ≥75 years. Results The prevalence of comorbidities was 71.6%, with older participants (≥75 years) showing a significantly higher burden, including bone diseases, osteoarthritis, and dementia (P<0.001). Polypharmacy was observed in 28.4% of participants and increased with age, with 53.3% of those aged ≥75 years taking ≥10 pills daily. Polypharmacy was associated with poorer QOL (71.6 vs. 76.6, P=0.010). Amber-flag DDIs were found in 81 participants (33.3%), most commonly involving metformin and divalent cations. No red-flag DDIs were identified. PIMs were observed in 6.6% of participants aged ≥65 years. Conclusion Aging PLWH in Korea face significant challenges from comorbidities, polypharmacy, and DDIs, which negatively impact QOL. Integrated, age-specific, and multidisciplinary care strategies are urgently needed to improve outcomes and ensure the well-being of older PLWH.
Abstract
Background The life expectancy of people living with human immunodeficiency virus (PLWH) has significantly improved with advancements in antiretroviral therapy (ART). However, aging PLWH face a growing burden of non-communicable diseases (NCDs), polypharmacy, and drug-drug interactions (DDIs), which pose challenges in their management. This study investigates the prevalence of NCDs, polypharmacy, and DDIs among PLWH aged ≥50 years in Korea and their impact on quality of life (QOL). Materials and Methods A cross-sectional study was conducted among 243 PLWH aged ≥50 years receiving ART for at least three months at three university hospitals in Korea between January and July 2022. Data were collected through electronic medical records and personal interviews, assessing demographics, comorbidities, polypharmacy, ART adherence, and QOL using the Korean version of WHOQOL-HIV BREF scale. Potential DDIs were analyzed using the University of Liverpool HIV Drug Interaction Database, and potentially inappropriate medications (PIMs) were identified using the 2023 American Geriatrics Society Beers Criteria. We classified participants into three age groups: 50–<65 years, 65–<75 years, and ≥75 years. Results The prevalence of comorbidities was 71.6%, with older participants (≥75 years) showing a significantly higher burden, including bone diseases, osteoarthritis, and dementia (P<0.001). Polypharmacy was observed in 28.4% of participants and increased with age, with 53.3% of those aged ≥75 years taking ≥10 pills daily. Polypharmacy was associated with poorer QOL (71.6 vs. 76.6, P=0.010). Amber-flag DDIs were found in 81 participants (33.3%), most commonly involving metformin and divalent cations. No red-flag DDIs were identified. PIMs were observed in 6.6% of participants aged ≥65 years. Conclusion Aging PLWH in Korea face significant challenges from comorbidities, polypharmacy, and DDIs, which negatively impact QOL. Integrated, age-specific, and multidisciplinary care strategies are urgently needed to improve outcomes and ensure the well-being of older PLWH.
참고문헌 (27)
- Wandeler G, "Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe : comparisons with general population", Curr Opin HIV AIDS, 11, pp.492~500 (2016)
- Guaraldi G, "The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients : a cross sectional study of people aged 65-74 years and more than 75 years", BMC Geriatr, 18, pp.99~ (2018)
- GBD 2019 South Korea BoD Collaborators, "Population health outcomes in South Korea 1990-2019, and projections up to 2040 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet Public Health, 8, pp.e639~e650 (2023)
- Kim JH, "Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls : a nationwide population-based study in South Korea", HIV Med, 22, pp.824~833 (2021)
- Marzolini C, "Ageing with HIV : medication use and risk for potential drug-drug interactions", J Antimicrob Chemother, 66, pp.2107~2111 (2011)
- Back D, "The challenge of HIV treatment in an era of polypharmacy", J Int AIDS Soc, 23, pp.e25449~ (2020)
- Choi JP, "HIV-related stigma reduction in the era of undetectable equals untransmittable : the South Korean perspective", Infect Chemother, 53, pp.661~675 (2021)
- Kwon S, "Social stigma and discrimination towards people living with HIV infection and AIDS patients", J Korean Med Assoc, 67, pp.194~203 (2024)
- "Drug safety, drug information search"[URL]
- Ambrosioni J, "Major revision version 12. 0 of the European AIDS Clinical Society guidelines 2023", HIV Med, 24, pp.1126~1136 (2023)
- Knobel H, "Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients : the GEEMA Study", AIDS, 16, pp.605~613 (2002)
- Lee WK, "Development of quality of life with WHOQOL-HIV BREF Korean version among HIV patients in Korea", JKDISS, 25, pp.337~347 (2014)
- Min SK, "Development of the Korean versions of WHO Quality of Life scale and WHOQOL-BREF", Qual Life Res, 11, pp.593~600 (2002)
- "Liverpool HIV interactions"[URL]
- By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel, "American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults", J Am Geriatr Soc, 71, pp.2052~2081 (2023)
- Sarma P, "Ageing with HIV : medicine optimisation challenges and support needs for older people living with HIV : a systematic review", Drugs Aging, 40, pp.179~240 (2023)
- Patel R, "An observational study of comorbidity and healthcare utilisation among HIV-positive patients aged 50 years and over", Int J STD AIDS, 27, pp.628~637 (2016)
- Siefried KJ, "Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy", AIDS, 32, pp.35~48 (2018)
- Farahat FM, "The prevalence of comorbidities among adult people diagnosed with HIV infection in a tertiary care hospital in western Saudi Arabia", J Infect Public Health, 13, pp.1699~1704 (2020)
- Jacomet C, "Pharmacist’s role in HIV care in France. Implication for clinical improvement of people living with HIV worldwide", Pharmacol Res Perspect, 8, pp.e00629~ (2020)
- Fischetti B, "Evaluation of rates of virologic suppression in HIV-positive patients with varying numbers of comorbidities", Am J Health Syst Pharm, 79, pp.72~77 (2022)
- "Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"[URL]
- Baecke C, "Prevalence of drug-drug interactions in the era of HIV integrase inhibitors : a retrospective clinical study", Neth J Med, 75, pp.235~240 (2017)
- Courlet P, "Polypharmacy, drug-drug interactions, and inappropriate drugs : new challenges in the aging population with HIV", Open Forum Infect Dis, 6, pp.ofz531~ (2019)
- Deutschmann E, "Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors", Clin Infect Dis, 73, pp.e2145~e2152 (2021)
- Loste C, "Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort : does the current prevalence give cause for concern?", Br J Clin Pharmacol, 87, pp.1310~1317 (2021)
- Choi JP, "The story and implications of the Korean health care facility counseling project on people living with HIV", Infect Chemother, 55, pp.167~178 (2023)